Leukemia, Lymphoid: all 1,772 studies
Page 2 of 18. Open to participants first (173), then studies with results posted, then the rest; newest registration first within each.
- Familial B-cell Lymphoproliferative DisordersNot yet recruitingNCT05718986
- Ibrutinib for the Treatment of AIHA in Patients With CLL/SLL or CLL-like MBLRecruitingNCT05694312Phase 2
- ThisCART19A Bridging to alloHSCT for R/R B-ALLRecruitingNCT05679687Phase 1
- To Evaluate the Safety and Efficacy of Human CD19 Targeted DASH CAR-T Cells Injection for Subjects With R/R B-ALLRecruitingNCT05651191Early Phase 1
- CD19-Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory B-Lineage Leukaemia / Lymphoma - A Feasibility ProtocolRecruitingNCT05648019Phase 2
- Severe Toxicity Free Survival Following Childhood Acute Lymphoblastic LeukemiaRecruitingNCT05639673
- Clinical Study of Senl-T7 CAR T Cells in the Treatment of Relapsed and Refractory CD7+ Acute T-ALL/T-LBLRecruitingNCT05626400Not applicable
- Modified TBF Regimen as Conditioning Regimen Prior to Allo-HSCT for T-ALL/LBLRecruitingNCT05598593Phase 2
- CD5 CAR-T Therapy for Refractory/Relapsed CD5+ T-cell Acute Lymphoblastic LeukemiaRecruitingNCT05596266Phase 1
- Blinatumomab as a Bridge to Allo-HSCT in HR BCP-ALLRecruitingNCT05559450Phase 2
- Effectiveness and Safety of Tisagenlecleucel Therapy in Brazilian Patients With B-lymphocyte MalignanciesRecruitingNCT05541341
- Use of Levocarnitine to Reduce Asparaginase Hepatotoxicity in Patients With Acute Lymphoblastic LeukemiaRecruitingNCT05501899Early Phase 1
- Laser Therapy Effect on Oral Mucositis in Childhood Acute Lymphoblastic Leukemia PatientsRecruitingNCT05452668Not applicable
- Dual Anti-CD22/CD19 Chimeric Antigen Receptor-directed T Cells (CART2219.1) for Relapsed Refractory B-Lineage LeukaemiaRecruitingNCT05429905Phase 1/2
- Base Edited CAR7 T Cells to Treat T Cell Malignancies (TvT CAR7)RecruitingNCT05397184Phase 1
- Polymorphism of ITGA4 Gene in Chronic Lymphocytic LeukemiaNot yet recruitingNCT05371392
- Ibrutinib Adapted to Response in Patients With CLLNot yet recruitingNCT05360758
- Evaluation of the Ambulatory Medical Assistance Nurse Program in Chronic Lymphocytic LeukemiaRecruitingNCT05350826Not applicable
- Pilot CAR-T Cells Therapy for Children/Young Adults With CD19+ R/R Leukemia/LymphomaRecruitingNCT05333302Phase 1
- Combination of an Anti-PD1 Antibody With Tisagenlecleucel Reinfusion in Children, Adolescents and Young Adults With Acute Lymphoblastic Leukemia After Loss of PersistenceRecruitingNCT05310591Phase 1/2
- Clinical Trial to Evaluate the Safety and Efficacy of IM19 CAR-T Cells in Patients With Relapsed and Refractory (R/R) B-cell Acute Lymphoblastic LeukemiaNot yet recruitingNCT05309213Phase 1/2
- Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic LeukemiaRecruitingNCT05281809Phase 2
- A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)RecruitingNCT05254743Phase 3
- Venetoclax Resistance Landscape in Chronic Lymphocytic LeukemiaRecruitingNCT05246345
- Clinical Study of Hospital-manufactured CD19 CAR-T in Children and Adolescents With Acute Lymphoblastic LeukemiaRecruitingNCT05210907Phase 1
- Selenious Yeast in CLL Patients w/o Indication of ChemotherapyRecruitingNCT05136378Not applicable
- RWE of Pediatric-like Protocol for AYA Patients With Ph-negative ALLRecruitingNCT05127148
- CD19 Targeted Universal Chimeric Antigen Receptor T Cells Injection for CD19+ Refractory/Relapsed B-cell MalignanciesRecruitingNCT05105867Early Phase 1
- Profiling Program of Cancer Patients With Sequential Tumor and Liquid Biopsies (PLANET)RecruitingNCT05099068Not applicable
- A Phase 1b-2 Trial to Assess Venetoclax and Navitoclax Consolidation and Post-transplant Maintenance in High-risk Patients With T-ALLNot yet recruitingNCT05054465Phase 1/2
- CART19 Cells Effects in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Non-Hodgkin's LymphomaRecruitingNCT05054257Phase 1
- CARTALL: Chimeric-Antigen Receptor (CAR) T-Cell Therapy for Relapsed/ Refractory T-Lineage Acute Lymphoblastic LeukaemiaRecruitingNCT05043571Phase 1
- ALaCART-B: Acute Leukemia and Chimeric Antigen Receptor-T Cell Therapy for B-lymphoblastic Leukemia.RecruitingNCT05038696Phase 1
- Combined Immuno-chemotherapy for Patients With B-linear Acute Lymphoblastic Leukemia Diagnosed From 0 to 365 Days of Life (ALL-Baby-2021)RecruitingNCT05029531Phase 3
- Zebutinib Combined With Immunochemotherapy in the Treat of Newly Treated CLL Patients Without 17p-/TP53 MutationNot yet recruitingNCT04980859Phase 3
- Monitoring Minimal Residual Disease（MRD）in Pediatric B-acute Lymphoblastic LeukemiaRecruitingNCT04977895
- Study on the Diagnosis and Management of CLL in Italy by GIMEMARecruitingNCT04867915
- Clinical Study of ssCART-19 Cells in Patients With CD19 Positive Relapsed or Refractory Acute Lymphoblastic LeukemiaRecruitingNCT04825496Phase 1
- A Pilot Study on Intermittent Ibrutinib in Patients With Advanced-phase Chronic Lymphocytic Leukemia (CLL)RecruitingNCT04771507Phase 1/2
- Quantitative MRI of Bone Marrow in Patients With Acute Lymphoblastic LeukemiaRecruitingNCT04767165Not applicable
- Venetoclax, Rituximab and Ibrutinib in TN Patients With CLL Undetectable Minimal Residual Disease (uMRD) in Treatment-naïve Patients With Chronic Lymphocytic Leukemia (CLL)RecruitingNCT04758975Phase 2
- Blinatumomab After TCR Alpha Beta/CD19 Depleted HCTRecruitingNCT04746209Phase 2
- Study in Adult Ph-positive ALLNot yet recruitingNCT04688983Phase 2
- Pharmacokinetics of Venetoclax in Patients With Chronic Lymphocytic LeukemiaRecruitingNCT04616274
- CD79b CAR-T Cell Therapy for Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia and B-cell Non-Hodgkin's LymphomaNot yet recruitingNCT04609241Early Phase 1
- CAR-T Cells Combined With Dasatinib for Patients With Relapsed and/or Refractory B-cell Hematological MalignanciesRecruitingNCT04603872Early Phase 1
- A Study of GC019F CAR-T Cell Immunotherapy for Relapsed or Refractory B- ALLNot yet recruitingNCT04595162Phase 1
- Advancing Chemical and Genomic Strategies for Relapsed/Refractory T-ALL and ETP-ALLRecruitingNCT04582487Not applicable
- ICP-022 Versus Chlorambucil Combined With Rituximab in the Treatment of Untreated CLL/SLLRecruitingNCT04578613Phase 3
- Study of IFN-α Combined With CAR-T Cell Therapy in Relapsed and Refractory Acute Lymphoblastic Leukemia（R/R-ALL）RecruitingNCT04534634Phase 2
- A Study of Murine CD19 CAR-T Therapy for Patients With Relapsed or Refractory CD19+ B-cell Hematological MalignanciesRecruitingNCT04532281Early Phase 1
- A Study of Humanized CD19 CAR-T Cells Therapy for Patients With Relapsed and/or Refractory B-cell ALL and B-cell NHLRecruitingNCT04532268Early Phase 1
- A Study of CAR-T Cells Therapy for Patients With Relapsed and/or Refractory Central Nervous System Hematological MalignanciesRecruitingNCT04532203Early Phase 1
- Study of APG2575 Single Agent and Combination Therapy in Patients With Relapsed/Refractory CLL/SLLRecruitingNCT04494503Phase 1/2
- CD19+Targeted CAR-T Cell Therapy for Relapsed/Refractory CD19+ B Cell Leukemia and LymphomaRecruitingNCT04271410Phase 1/2
- A Prospective Multicenter Phase 2 Study of FCR/BR Alternating With Ibrutinib in Treatment-naive Patients With CLLRecruitingNCT03980002Phase 2
- Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS)RecruitingNCT03970096Phase 2
- Intravenous Autologous CD19 CAR-T Cells for R/R B-ALLRecruitingNCT03937544Phase 2/3
- Allogeneic Hematopoietic Cell Transplantation From HLA-matched Donor After Flu-Mel-PTCy Versus Flu-Mel-ATG Reduced-intensity ConditioningRecruitingNCT03852407Phase 2
- Treatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Cells Expressing a Third-generation CARRecruitingNCT03676504Phase 1/2
- 211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic SyndromeRecruitingNCT03670966Phase 1/2
- Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017RecruitingNCT03643276Phase 3
- The EndRAD Trial: Eliminating Total Body Irradiation (TBI) for NGS-MRD Negative Children, Adolescents, and Young Adults With B-ALLRecruitingNCT03509961Phase 2
- Inotuzumab Ozogamicin and Conventional Chemotherapy In Patients Aged 56 Years and Older With ALLRecruitingNCT03460522Phase 2
- Childhood Acute Lymphoblastic Leukemia Treatment Protocol Moscow-Berlin 2015 (ALL-MB 2015)RecruitingNCT03390387Not applicable
- Chronic Lymphoid Leukaemia Observatory in Finistere Area, FranceRecruitingNCT03294980
- A Personalized Neoantigen Cancer Vaccine in Treatment Naïve, Asymptomatic Patients With IGHV Unmutated CLL.RecruitingNCT03219450Phase 1
- Chronic Lymphocytic Leukemia Registry Study - Multicenter Prospective National StudyRecruitingNCT03197259
- CAR-T Therapy for Central Nervous System B-cell Acute Lymphocytic LeukemiaRecruitingNCT03064269Phase 1
- Institut Paoli Calmettes Chronic Lymphatic Leukemia DatabaseRecruitingNCT02869529
- ALL SCTped FORUM - Pharmacogenomic Study (add-on Study)RecruitingNCT02670564Phase 4
- KIR Favorable Mismatched Haplo Transplant and KIR Polymorphism in ALL/AML/MDS Allo-HCT ChildrenEnrolling by invitationNCT02646839Phase 2
- Multicenter Trial Treatment of Philadelphia Chromosome Negative B-cell Acute Lymphoblastic Leukemia of Young AdultsRecruitingNCT02617004
- Insomnia Prevention in Children With Acute Lymphoblastic LeukemiaCompletedNCT05866887Not applicableResults posted
- A Study of Patients Who Received Inotuzumab Ozogamicin for B-cell ALL (Acute Lymphoblastic Leukemia) That Occurred Again After the Last TreatmentCompletedNCT05597085Results posted
- Myeloablative Conditioning Orca-T & Allogeneic Donor-Derived CD19/CD22-CAR TCells in B-Cell ALLActive, not recruitingNCT05507827Phase 1Results posted
- RP-3500 and Olaparib in DNA Damage Repair Pathway Deficient Relapsed/Refractory Chronic Lymphocytic LeukemiaTerminatedNCT05405309Phase 1/2Results posted
- T-cell Receptor α/β Depleted Donor Lymphocyte InfusionTerminatedNCT05350163Phase 1Results posted
- Latin American Real-world Study in Acute LeukemiaCompletedNCT05166135Results posted
- A Roll-over Study to Provide Continued Treatment With Lyophilized Pegaspargase (S95014) in Pediatric Patients With Acute Lymphoblastic Leukemia (ALL)CompletedNCT04956666Phase 2Results posted
- A Study Comparing the Blood Levels of Both Pegaspargase (S95014) Formulations (Liquid vs Lyophilized) in the Treatment of Paediatric Patients With Acute Lymphoblastic Leukemia (ALL)CompletedNCT04954326Phase 2Results posted
- Acalabrutinib Study in Indian Patients With Chronic Lymphocytic Leukaemia & Relapsed and Refractory Mantle Cell LymphomaCompletedNCT04930536Phase 4Results posted
- A Study of LOXO-305 in Chinese Participants With Blood Cancer (Including Lymphoma and Chronic Leukemia)CompletedNCT04849416Phase 2Results posted
- DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic LeukemiaTerminatedNCT04752163Phase 1/2Results posted
- Blinatumomab Bridging Therapy for BALLTerminatedNCT04556084Phase 2Results posted
- Blinatumomab in Combination With AMG 404 for the Treatment of Adults With Relapsed or Refractory B Cell Precursor ALLCompletedNCT04524455Phase 1Results posted
- Feasibility Study to Evaluate Outpatient Blinatumomab in Subjects With Minimal Residual Disease (MRD) of B-precursor Acute Lymphoblastic Leukemia (ALL)TerminatedNCT04506086Phase 4Results posted
- InO - A Retrospective Study of UK Patients With LeukaemiaCompletedNCT04456959Results posted
- APR-246 in Combination With Acalabrutinib or Venetoclax Based Therapy in Subjects With R/R Non Hodgkin Lymphomas (NHL)TerminatedNCT04419389Phase 1/2Results posted
- Study of Efficacy and Safety of Reinfusion of Tisagenlecleucel in Pediatric and Young Adult Patients With Acute Lymphoblastic Leukemia (ALL)TerminatedNCT04225676Phase 2Results posted
- Duvelisib for Ibrutinib-Resistant Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaTerminatedNCT04209621Phase 2Results posted
- Efficacy and Safety of Tenalisib (RP6530) in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)CompletedNCT04204057Phase 2Results posted
- Acalabrutinib in Combination With R-ICE For Relapsed or Refractory LymphomaTerminatedNCT04189952Phase 2Results posted
- T Cells Expressing Fully-human Anti-CD19 and Anti-CD20 Chimeric Antigen Receptors for Treating B-cell Malignancies and Hodgkin LymphomaTerminatedNCT04160195Phase 1Results posted
- Bendamustine and Rituximab in Combination With Copanlisib for the Treatment of Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaTerminatedNCT04155840Phase 2Results posted
- An Open-Label Study of JZP-458 (RC-P) in Patients With Acute Lymphoblastic Leukemia (ALL)/Lymphoblastic Lymphoma (LBL)CompletedNCT04145531Phase 2/3Results posted
- A Clinical Study of SHP674 (Pegaspargase) in Participants With Newly Diagnosed, Untreated Acute Lymphoblastic LeukemiaCompletedNCT04067518Phase 2Results posted
- Dose-escalation Study of Safety of PBCAR20A in Subjects With r/r NHL or r/r CLL/SLLCompletedNCT04030195Phase 1/2Results posted
- Study to Assess the Efficacy and Safety of Ublituximab and Umbralisib in Participants With Chronic Lymphocytic Leukemia (CLL) Currently Treated With Ibrutinib, Acalabrutinib or VenetoclaxTerminatedNCT04016805Phase 2Results posted
- PO Ixazomib in Combination With Chemotherapy for Childhood Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic LymphomaActive, not recruitingNCT03817320Phase 1/2Results posted